Morgan Stanley’s Xenetic Biosciences XBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $437 | Buy |
+150
| New | +$463 | ﹤0.01% | 7699 |
|
|
2026
Q1 | – | Sell |
-3
| Closed | -$7 | – | 8522 |
|
|
2025
Q4 | $7 | Sell |
3
-1
| -25% | -$3 | ﹤0.01% | 8147 |
|
|
2025
Q3 | $12 | Hold |
4
| – | – | ﹤0.01% | 8091 |
|
|
2025
Q2 | $16 | Hold |
4
| – | – | ﹤0.01% | 8014 |
|
|
2025
Q1 | $11 | Buy |
4
+3
| +300% | +$12 | ﹤0.01% | 8011 |
|
|
2024
Q4 | $4 | Hold |
1
| – | – | ﹤0.01% | 7938 |
|
|
2024
Q3 | $4 | Hold |
1
| – | – | ﹤0.01% | 7896 |
|
|
2024
Q2 | $4 | Hold |
1
| – | – | ﹤0.01% | 7816 |
|
|
2024
Q1 | $4 | Sell |
1
-1
| -50% | -$4 | ﹤0.01% | 7791 |
|
|
2023
Q4 | $6 | Sell |
2
-293
| -99% | -$1.03K | ﹤0.01% | 7795 |
|
|
2023
Q3 | $1.45K | Hold |
295
| – | – | ﹤0.01% | 7181 |
|
|
2023
Q2 | $967 | Hold |
295
| – | – | ﹤0.01% | 7300 |
|
|
2023
Q1 | $1.2K | Sell |
295
-302
| -51% | -$1.47K | ﹤0.01% | 7327 |
|
|
2022
Q4 | $1.7K | Buy |
597
+2
| +0.3% | +$9 | ﹤0.01% | 7396 |
|
|
2022
Q3 | $4K | Sell |
595
-670
| -53% | -$5.29K | ﹤0.01% | 7332 |
|
|
2022
Q2 | $10K | Sell |
1,265
-2
| -0.2% | -$16 | ﹤0.01% | 7214 |
|
|
2022
Q1 | $13K | Buy |
1,267
+2
| +0.2% | +$21 | ﹤0.01% | 7319 |
|
|
2021
Q4 | $16K | Buy |
1,265
+747
| +144% | +$11.9K | ﹤0.01% | 7307 |
|
|
2021
Q3 | $11K | Buy |
518
+292
| +129% | +$7.96K | ﹤0.01% | 7292 |
|
|
2021
Q2 | $5K | Hold |
226
| – | – | ﹤0.01% | 7399 |
|
|
2021
Q1 | $5K | Buy |
226
+200
| +769% | +$5.26K | ﹤0.01% | 7117 |
|
|
2020
Q4 | $1K | Hold |
26
| – | – | ﹤0.01% | 6976 |
|
|
2020
Q3 | $0 | Hold |
26
| – | – | ﹤0.01% | 6839 |
|
|
2020
Q2 | $0 | Hold |
26
| – | – | ﹤0.01% | 6735 |
|
|
2020
Q1 | $0 | Hold |
26
| – | – | ﹤0.01% | 6721 |
|
|
2019
Q4 | $0 | Hold |
26
| – | – | ﹤0.01% | 6777 |
|
|
2019
Q3 | $0 | Sell |
26
-3,582
| -99% | -$128K | ﹤0.01% | 6769 |
|
|
2019
Q2 | $406K | Buy |
3,608
+3,582
| +13,777% | +$474K | ﹤0.01% | 4713 |
|
|
2019
Q1 | $6K | Hold |
26
| – | – | ﹤0.01% | 6301 |
|
|
2018
Q4 | $5K | Buy |
26
+1
| +4% | +$303 | ﹤0.01% | 6302 |
|
|
2018
Q3 | $9K | Sell |
25
-1
| -4% | -$390 | ﹤0.01% | 6334 |
|
|
2018
Q2 | $13K | Buy |
26
+9
| +53% | +$2.3K | ﹤0.01% | 6244 |
|
|
2018
Q1 | $4K | Hold |
17
| – | – | ﹤0.01% | 6432 |
|
|
2017
Q4 | $4K | Hold |
17
| – | – | ﹤0.01% | 6366 |
|
|
2017
Q3 | $4K | Hold |
17
| – | – | ﹤0.01% | 6330 |
|
|
2017
Q2 | $6K | Sell |
17
-32
| -65% | -$13.6K | ﹤0.01% | 6327 |
|
|
2017
Q1 | $27K | Hold |
49
| – | – | ﹤0.01% | 5996 |
|
|
2016
Q4 | $26K | Buy |
+49
| New | +$21.1K | ﹤0.01% | 5938 |
|
Other funds holding XBIO
JEST
SS
TRCT
DWM
Morgan Stanley's XBIO Position: Q2 2026 in Review
Morgan Stanley opened a new position in Xenetic Biosciences (XBIO) in Q2 2026: 150 shares worth $437. The stake represents ﹤0.01% of the portfolio and ranks #7699 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in XBIO as recently as Q4 2025.
Morgan Stanley first reported a position in XBIO in Q4 2016 and has held it in 38 quarters since. The position peaked at $406K in Q2 2019. 8 funds tracked by Wall St. Rank hold XBIO as of Q2 2026.
- Morgan Stanley held 150 shares of Xenetic Biosciences worth $437 as of Q2 2026.
- Xenetic Biosciences was a new Morgan Stanley position in Q2 2026.
- Xenetic Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7699 holding.
- Morgan Stanley first reported a position in Xenetic Biosciences in Q4 2016 and has held it in 38 quarters since.
- Morgan Stanley's Xenetic Biosciences position peaked at $406K in Q2 2019.
- 8 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.